[News] Ready-to-use T cells for infection after stem-cell transplant

00:02 EDT 18 Aug 2017 | The Lancet

A new phase 2 trial suggests that cryopreserved virus-specific T cells (VSTs) prepared from third-party donors are a safe and effective treatment for recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) who develop drug-refractory viral infections. Viral infection is a common, life-threatening complication for these patients, and drug treatment can be ineffective or have substantial side-effects.

Original Article: [News] Ready-to-use T cells for infection after stem-cell transplant


More From BioPortfolio on "[News] Ready-to-use T cells for infection after stem-cell transplant"

Quick Search


Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...